drugset / Trial / NCT00791154

QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer

NCT00791154 ↗

Phase 1/2 Terminated 213 enrolled NantCell, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is titled "A Phase 1b/2 trial of AMG 479 or AMG 102 with Platinum-Based Chemotherapy as First-Line Treatment for Extensive Stage Small-Cell Lung Cancer (SCLC)." Part 1, the phase 1b portion of this study, is a multicenter, open-label investigation to identify safe dose levels of either AMG 102 or AMG 479 in combination with etoposide plus cisplatin or carboplatin in subjects with previously untreated extensive stage SCLC. Part 2, the phase 2 portion of this study, is a multicenter, double-blind, 3-arm investigation to evaluate overall survival of either AMG 102 or AMG 479 in combination with platinum-based chemotherapy.

Timeline

Start
2008-12-02
Primary completion
2010-02-02
Completion
2013-05-01

Outcome

Outcome not reported

Stopped: “Subjects discontinued study”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganitumab Monoclonal antibody — —
Subject Rilotumumab Monoclonal antibody — —
Background Carboplatin Small molecule — —
Background Cisplatin Other / unclassified — —
Background Etoposide Small molecule — —